Skip to main content

Aimee Jackson, Anastasia Khvorova, Dave Rozema

Regulus Therapeutics has appointed Aimee Jackson as its director of drug discovery.
Jackson previously served as a senior research fellow at Rosetta Inpharmatics, a unit of Merck. Earlier this year, Regulus announced that it had hired Peter Linsley, who had previously held various positions at Rosetta and Merck, as its CSO.
Jackson holds a PhD from the University of Colorado Health Science Center.

RXi Pharmaceuticals has named Anastasia Khvorova as its CSO.
Khvorova most recently served as CSO and vice president of research and development of Dharmacon, now a division of Thermo Fisher Scientific. Before joining Dharmacon, she was a research scientist at Amgen.

The Wisconsin Biotechnology & Medical Device Association has named Dave Rozema, a senior scientist at Roche subsidiary Mirus Bio, a winner of this year’s annual Rising Stars award.
According to WBMA, the awards recognize the biotech and medical device industries’ “next generation of leaders” based on their efforts at their particular company.
Rozema led the chemistry team that developed Mirus’ dynamic polyconjugate siRNA delivery technology, which was a major driver of Roche’s decision to acquire the company, WBMA said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.